Celiprolol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Celiprolol
Celiprolol.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Pharmacokinetic data
Bioavailability30-70%
Elimination half-life5 hours
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.054.980 Edit this at Wikidata
Chemical and physical data
FormulaC20H33N3O4
Molar mass379.49 g/mol g·mol−1
3D model (JSmol)
ChiralityRacemic mixture

Celiprolol is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.

Celiprolol is believed to provide clinical benefit for people with vascular Ehlers–Danlos syndrome by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.[1] Acer Therapeutics is currently developing celiprolol as a potential treatment option specifically for people with vEDS. In 2015, the U.S. Food and Drug Administration (FDA) granted celiprolol orphan drug designation for the treatment of vascular Ehlers–Danlos syndrome.

It was patented in 1973 and approved for medical use in 1982.[2]

Brand names[edit]

Brand names include Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm

References[edit]

  1. ^ Beridze N, Frishman WH (2012). "Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications". Cardiol Rev. 1: 4–7. doi:10.1097/CRD.0b013e3182342316. PMID 22143279.
  2. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 461. ISBN 9783527607495.

External links[edit]